-
BeiGene Secures Exclusive Licensing Deal with Duality Biotherapeutics for Novel Drug Development
•
China-based BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has announced an exclusive option and licensing agreement with Duality Biotherapeutics, a novel modality drug developer with operations in both the United States and China. This strategic partnership aims to leverage Duality’s expertise in developing innovative therapies. Financial Terms and MilestonesAccording to…
-
Bayer and Peking University Enter Fourth Phase of Partnership to Advance Drug Discovery
•
Germany-based pharmaceutical giant Bayer (ETR: BAYN) has entered its fourth phase of partnership with the esteemed Peking University. This collaboration aims to strengthen the translation of basic research in key medical fields, including oncology, cardiovascular disease, kidney disease, immunity, and cell and gene therapy, with the goal of generating novel…
-
Transcenta Holding Ltd Secures Global Clinical Trial Approvals for Osemitamab in Gastric Cancer
•
China-based Transcenta Holding Ltd has reported receiving clinical trial approvals from China’s Center for Drug Evaluation (CDE) and South Korea’s Ministry of Food and Drug Safety (MFDS) for their pipeline candidate osemitamab (TST001), a CLDN18.2-targeted monoclonal antibody. Both regulatory bodies have approved the plan for TranStar 301, a global Phase…
-
Pentax Medical to Establish Endoscope Manufacturing and R&D Site in Shanghai
•
Japan-based Pentax Medical, a division of the Hoya Group specializing in endoscopic products, has announced plans to establish a new site in China focused on endoscope manufacturing, research and development (R&D), and the provision of related services. The facility will be located in Shanghai under the umbrella of Pentax Medical…
-
Sinopep-Allsino Bio Pharmaceutical Cuts Fundraising Target to RMB434 Million via Convertible Bonds”
•
Jiangsu-based Contract Development and Manufacturing Organization (CDMO) Sinopep-Allsino Biopharmaceutical Co., Ltd has revised its proposal for a convertible bond issuance, now expecting to raise RMB434 million, a decrease of RMB100 million compared to the initial target of RMB534 million set in November 2022. Proceeds Allocation for Strategic Projects and Working…
-
Shanghai BDgene Technology Receives US FDA Approval for HSV-1 Stromal Keratitis Gene Therapy
•
Gene therapy specialist Shanghai BDgene Technology Co., Ltd has announced receiving approval from the US FDA to conduct a clinical study for its pipeline candidate, BD111, in the treatment of type I herpes simplex virus (HSV-1) stromal keratitis. HSV-1 is a pathogen responsible for a range of diseases, including oral…
-
Jenscare Scientific’s LuX-Valve Plus Accepted for US FDA Review in IDE Process
•
Ningbo-based structural heart disease intervention device manufacturer, Jenscare Scientific Co., Ltd (HKG: 9877), has announced that the early feasibility study (EFS) pre-submission for its LuX-Valve Plus has been accepted for review by the US FDA. This filing marks the initiation of the Investigational Device Exemption (IDE) process in the United…
-
Broncus Medical Inc. Launches First Regulatory Clinical Study for Targeted Lung Denervation System
•
China-based Broncus Medical Inc., (HKG: 2216), a provider of precision intervention solutions focused on lung diseases, has announced the start of its first regulatory clinical study for its targeted lung denervation (TLD) radiofrequency ablation system. This multi-center, randomized study will be conducted across 26 centers, aiming to assess the safety…
-
Hainan Boao Lecheng Partners with Medlive for Medical Tourism and Online Doctor Education
•
The Hainan Boao Lecheng International Medical Tourism Pilot Zone has entered into a strategic partnership with Medlive (HKG: 2192), a Beijing-based clinician-focused medical information service provider. This collaboration aims to fully leverage the strengths of both entities to enhance online doctor education and support a range of medical services. Expanding…
-
HutchMed Ltd Initiates Phase I Clinical Study for SHP2 Inhibitor HMPL-415 in Solid Tumors
•
China-based HutchMed Ltd (NASDAQ: HCM; HKG: 0013) has announced the initiation of a Phase I clinical study for its investigational novel selective allosteric inhibitor, HMPL-415, which targets Src homology-2 domain-containing protein tyrosine phosphatase-2 (SHP2). The trial, aimed at assessing the molecule in general solid tumors, marked its first patient dosing…
-
GenScript Biotech Expands cGMP Manufacturing for Gene and Cell Therapy in Zhenjiang Facility
•
China-based GenScript Biotech Corporation (HKG: 1548) has announced the expansion of its current Good Manufacturing Practice (cGMP) manufacturing capacity at a new facility located in Zhenjiang, Jiangsu province. This move is set to enhance the company’s ability to offer manufacturing services for sgRNA and non-viral DNA payloads, thereby better serving…
-
Jacobio Pharma Secures RMB 150 Million Investment to Advance Pipeline Programs
•
China-based Jacobio Pharma (HKG: 1167) has announced receiving RMB 150 million (USD 20.7 million) in funding from Beijing E-town International Investment & Development Co., Ltd. The investment is designated to support the research and development of the company’s pipeline programs, including the KRAS G12C-targeted glecirasib and other key projects. Jacobio’s…
-
Genesis MedTech Secures Chinese Market Approval for ArtiSential Laparoscopic Surgical Device
•
Singapore-based Genesis MedTech has announced that it has received market approval in China for its ArtiSential articulating laparoscopic surgical device. The device, originally developed by South Korean firm LivsMed, was exclusively licensed to Genesis for distribution and market development in China in a deal that took place in 2021. Innovative…
-
Shanghai Fosun Pharmaceutical Submits Daxibotulinumtoxin A (RT002) for NMPA Approval
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196), a China-based pharmaceutical company, has announced a market approval filing to the National Medical Products Administration (NMPA) in China for its in-licensed daxibotulinumtoxin A for injection (RT002). The drug has been filed for use in adult cervical dystonia, marking a significant step…
-
Jiangsu Hengrui Pharmaceuticals Receives NMPA Approval for SHR-1703 Clinical Study
•
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a China-based pharmaceutical company, has announced receiving approval from the National Medical Products Administration (NMPA) to initiate a clinical study for its anti-interleukin-5 (IL-5) antibody, SHR-1703. The drug candidate is set to be assessed as a treatment for eosinophilic granulomatous polyangiitis, a rare…
-
C-Mer Eye Care Holdings Ltd Partners with Hong Kong Ophthalmologist for Novel Drug Development
•
China-based C-Mer Eye Care Holdings Ltd (HKG: 3309) has announced the establishment of a joint venture with Doctor Dennis Lam, a distinguished ophthalmologist in Hong Kong. The joint venture, valued at a market capitalization of HKD 50 million (USD 6.4 million), is aimed at focusing on the development of innovative…
-
ChengDu ShengNuo Biotechnology Aims to Raise RMB 160 Million for Peptide Drug CDMO Expansion
•
China-based ChengDu Shengnuo Biotechnology Co., Ltd., (SHA: 688117) has announced plans to raise up to RMB 160 million (USD 22 million) through a private placement. The net proceeds from this capital increase are designated for Contract Development and Manufacturing Organization (CDMO) work on innovative peptide drugs, the industrialization of active…
-
Peijia Medical Receives NMPA Approval for DCwire Micro Guide Wire Device in China
•
Peijia Medical Ltd (HKG: 9996), a leading Chinese firm in the neurointerventional field, has announced receiving market approval from the National Medical Products Administration (NMPA) in China for its DCwire micro guide wire device. This milestone marks the company’s 15th neurointerventional product approval in China, highlighting its commitment to advancing…
-
Chime Biologics, Leads Biolabs, and BeiGene Form Strategic Partnership for LAG-3 mAb LBL-007
•
Wuhan-based Contract Development and Manufacturing Organization (CDMO) Chime Biologics has signed a strategic cooperation agreement with Nanjing-based Leads Biolabs and Beijing firm BeiGene Inc., (NASDAQ: BGNE, HKG: 6160). The cooperation focuses on the development and global manufacturing of LBL-007, a LAG-3 monoclonal antibody (mAb). BeiGene’s Acquisition and Global Rights to…
-
Sirnaomics Ltd Partners with Edirna Inc. to Advance RNA Editing Therapy
•
Sirnaomics Ltd (HKG: 2257), a leading company in the field of RNA therapeutics, has announced a strategic partnership with US-based Edirna Inc., a newly launched biotech startup focused on RNA editing therapy. Funding and Licensing Agreement DetailsUnder the terms of the agreement, Sirnaomics is providing start-up funding to support Edirna’s…
